Boireau A, Bordier F, Dubédat P, Pény C, Impérato A
Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.
Neurosci Lett. 1997 Oct 3;234(2-3):123-6. doi: 10.1016/s0304-3940(97)00685-x.
The effects of thalidomide, a sedative, anti-inflammatory and immunosuppressive agent were studied in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) murine model of Parkinson's disease. The striatal levels of dopamine (DA) and of its main metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured both in the MPTP control group (3 x 15 mg/kg intraperitoneally) and in the thalidomide groups (repeated treatments at 25 mg/kg or 50 mg/kg postoperatively). For mice treated with thalidomide, a dose-dependent protection was observed against the MPTP-induced decrease in DA. The decrease in HVA levels was totally antagonized by thalidomide at both doses. That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons.
在帕金森病的MPTP（1-甲基-4-苯基-1,2,3,6-四氢吡啶）小鼠模型中研究了镇静、抗炎和免疫抑制药物沙利度胺的作用。在MPTP对照组（腹腔注射3×15mg/kg）和沙利度胺组（术后以25mg/kg或50mg/kg重复给药）中均测量了纹状体中多巴胺（DA）及其主要代谢产物3,4-二羟基苯乙酸（DOPAC）和高香草酸（HVA）的水平。对于用沙利度胺治疗的小鼠，观察到对MPTP诱导的DA减少具有剂量依赖性保护作用。两种剂量的沙利度胺都完全拮抗了HVA水平的降低。沙利度胺在该模型中具有活性，这表明炎症过程可能参与了MPTP对多巴胺能神经元的损伤诱导。
